Predictive value of early molecular response to tyrosine kinase inhibitors in pediatric patients with chronic myeloid leukemia-Reference-Cited by-同舟云学术

Predictive value of early molecular response to tyrosine kinase inhibitors in pediatric patients with chronic myeloid leukemia

Published:2024-03-21 Issue:7 Volume:65 Page:1024-1027
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Abdallah Aya M.¹^ORCID,Hafez Hanafy¹²,Madney Youssef¹²,Ahmed Sonia¹²,Yassin Dina³⁴,Salem Sherine³⁴,Yousry Rodina⁵,Abdel-Azim Hisham⁶,Lehmann Leslie⁷,Elhaddad Alaa¹²

Affiliation:

1. Department of Pediatric Oncology, Children’s Cancer Hospital Egypt (CCHE 57357), Cairo, Egypt

2. Department of Pediatric Oncology, National Cancer Institute, Cairo University, Cairo, Egypt

3. Department of Clinical Pathology, Children’s Cancer Hospital Egypt (CCHE 57357), Cairo, Egypt

4. Department of Clinical Pathology, National Cancer Institute, Cairo University, Cairo, Egypt

5. Department of Research, Children’s Cancer Hospital (CCHE 57357), Cairo, Egypt

6. Cancer Center, Children Hospital and Medical Center, Loma Linda University, Loma Linda, CA, USA

7. Pediatric Stem Cell Transplantation Unit, Dana Farber Cancer Institute, Boston, MA, USA

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2024.2331625

Reference16 articles.

1. Surveillance Epidemiology and End Results (SEER) Program. Cancer Statistics Table 3.1: age-adjusted incidence rates and number of cases by period of diagnosis for major cancer sites and subsites; 2022; [cited 2022 Sep 7]. Available from: https://seer.cancer.gov/statistics/nccr/details.html

2. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia

3. Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology

4. Harmonization of molecular monitoring of CML therapy in Europe

5. Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – A Europe Against Cancer Program